ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Anti-TNF therapy and spondylarthropathy"

  • Abstract Number: 2229 • 2012 ACR/ARHP Annual Meeting

    Analysis of Clinical, CRP- and MRI- Responses to TNF-Blockade in Axial Spondyloarthritis Patients with Short Vs Long Symptom Duration

    Anja Weiss1, In-Ho Song2, Hildrun Haibel2, Joachim Listing3 and Joachim Sieper4, 1German Rheumatism Research Centre, Berlin, Germany, 2Medical Department I, Rheumatology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany, 3German Rheumatism Research Center, Berlin, Germany, 4Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany

    Background/Purpose: To investigate the impact of disease duration on treatment response in patients with axial spondylarthritis (SPA) treated with etanercept (ETA) or adalimumab (ADA). Methods:…
  • Abstract Number: 2220 • 2012 ACR/ARHP Annual Meeting

    Development of the Pulsar (Program to Understand the Longterm Outcomes in Spondyloarthritis) Registry

    Andreas M. Reimold1, Liron Caplan2, Daniel O. Clegg3, Gail S. Kerr4, Elizabeth Chang5, Lisa A. Davis6, Prashant Kaushik7, Vikas Majithia8, J. Steuart Richards9, Joel D. Taurog10 and Jessica Walsh11, 1Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX, 2Div of Rheumatology, Denver VA and Univ of Colorado School of Medicine, Aurora, CO, 3Division of Rheumatology, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, 4Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, 5Phoenix VAHCS, Phoenix, AZ, 6Division of Rheumatology, Denver Health and Hospital Authority, Denver, CO, 7Department of Medicine, Sratton VAMC, Albany, NY, 8Div of Rheumatology, University of Mississippi Medical Center, Jackson, MS, 9Rheumatology, Washington DC VA and Georgetown University, Washington, DC, 10Internal Medicine, Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, 11Rheumatology, University of Utah Hospital, Salt Lake City, UT

    Background/Purpose: The spondyloarthritides are a group of conditions characterized by inflammation in the axial skeleton or peripheral joints.  The arthritis may present as the primary…
  • Abstract Number: 539 • 2012 ACR/ARHP Annual Meeting

    Efficacy and Safety of Adalimumab for the Treatment of Peripheral Arthritis in Spondyloarthritis Patients without Ankylosing Spondylitis or Psoriatic Arthritis

    Jacqueline E. Paramarta1, Leen De Rycke2, Tanja F. Heijda2, Carmen A. Ambarus3, Koen Vos2, Huib J. Dinant2, Paul P. Tak2 and Dominique L. Baeten2, 1Department of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 2Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 3Department Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands

    Background/Purpose: The treatment of spondyloarthritis (SpA) has improved dramatically since the introduction of TNF-blockade. However, this therapy is only approved and reimbursed for the treatment…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology